Compare · APYX vs SYK
APYX vs SYK
Side-by-side comparison of Apyx Medical Corporation (APYX) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APYX and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $119.25B, about 674.2x APYX ($176.9M).
- Over the past year, APYX is up 125.8% and SYK is down 20.3% - APYX leads by 146.1 points.
- SYK has been more active in the news (4 items in the past 4 weeks vs 3 for APYX).
- SYK has more recent analyst coverage (25 ratings vs 9 for APYX).
- Company
- Apyx Medical Corporation
- Stryker Corporation
- Price
- $4.20-1.64%
- $311.25-6.14%
- Market cap
- $176.9M
- $119.25B
- 1M return
- -9.48%
- +1.90%
- 1Y return
- +125.81%
- -20.30%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 3
- 4
- Recent ratings
- 9
- 25
Apyx Medical Corporation
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and OEM. It offers electrosurgical generators based on its Helium Plasma Technology for cutting, coagulation, and ablation of soft tissue. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market that allows surgeons to operate with precision and eliminate unintended tissue trauma. It also develops, manufactures, and sells energy generators, disposable hand piece subassemblies, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest APYX
- H.C. Wainwright initiated coverage on Apyx Medical with a new price target
- Director Waldman Lawrence covered exercise/tax liability with 5,024 shares and exercised 12,000 shares at a strike of $1.88 (SEC Form 4)
- SEC Form DEF 14A filed by Apyx Medical Corporation
- Chief Operating Officer Roman Shawn David exercised 15,000 shares at a strike of $3.23 and covered exercise/tax liability with 10,533 shares (SEC Form 4)
- SEC Form 8-K filed by Apyx Medical Corporation
- SEC Form 4 filed by Director Levine Wendy Lauren
- Director Vizirgianakis Stavros G. was granted 450,000 units of Restricted Stock Units, increasing direct ownership by 26% to 2,196,191 units (SEC Form 4)
- SEC Form 4 filed by Chief Executive Officer Goodwin Charles D. Ii
- SEC Form 4 filed by Chief Financial Officer Hill Matthew C
- SEC Form 4 filed by Chief Operating Officer Roman Shawn David
Latest SYK
- BMO Capital Markets initiated coverage on Stryker with a new price target
- Stryker to announce second quarter 2026 financial results
- Stryker Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Stryker partners with professional golfer Shane Lowry to spotlight the caregiver journey in joint replacement
- Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower
- President and COO Stiles Spencer S gifted 1,607 shares, decreasing direct ownership by 2% to 76,027 units (SEC Form 4)
- Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
- VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)
- Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)
- Stryker Launches Pangea Plating System and Completes First Case in Europe